VRNA News and Press, Verona Pharma plc From 02/01/24

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings a wealth of strategic and operational experience in the bio...

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

2024-01-23 03:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-19 17:30:12 ET Summary Verona Pharma plc develops respiratory disease medicines, with its lead asset being ensifentrine, an inhaled dual inhibitor of PDE3 and PDE4 enzymes. Ensifentrine is being developed in multiple formulations and is currently under FDA review for the t...

2024-01-13 12:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets appear to have...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan...

2024-01-02 04:56:29 ET More on Verona Pharma Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript Verona Pharma GAAP EPS of -$0.02 beats by $0.14 Seeking Alpha’s ...

LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”...

2023-12-30 06:50:00 ET Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be monster winners in 2024. H...